The high expression of mutiple feedback inhibitors, together with high expression of GZMB and IFN‐γ in CIC2, identifies ongoing, or at least prior, immune activation in a subset of GBM patients, restrained by the action of these inhibitory pathways. The gene discussed is GZMB; the disease is glioblastoma.